Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGB101 for the Treatment of Hippocampal Overactivity in the Elderly
NCT06919926Phase 2Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Apr 2025
- Primary completion
- May 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levetiracetam in hippocampal overactivity and Dementia (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Change in hippocampal overactivity at 8 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
levetiracetam
03
Conditions
hippocampal overactivityDementia
Beyond the preview
Go deeper on NCT06919926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919926.